Study finds HFCWO Therapy using Philips InCourage System reduces hospitalizations
Study finds HFCWO Therapy using Philips InCourage System reduces hospitalizations
July 23, 2020
2020年7月23日
Amsterdam, the Netherlands –Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the publication of a peer-reviewed, retrospective outcomes study demonstrating that, in the first year of use, high frequency chest wall oscillation therapy (HFCWO) using thePhilips InCourage Systemreduced the rate of chronic respiratory patient hospitalization by more than 50 percent. According to the study, antibiotic use also decreased significantly. The study examined data from a registry of adult bronchiectasis patients’ self-reported outcomes collected by RespirTech, a Philips company. This data repository is now thelargest bronchiectasis research registryin the world.
荷蘭阿姆斯特丹--皇家飛利浦(RAPL.O：行情)紐約證券交易所：PHG全球醫療技術領先企業飛利浦電子科技公司(AEX：PHIA)今天宣佈發表一項同行評議的回顧性研究結果，結果顯示，在使用的第一年，使用飛利浦Inourage系統的高頻胸壁振盪療法(HFCWO)將慢性呼吸道患者的住院率降低了50%以上。根據這項研究，抗生素的使用也顯著減少。這項研究檢查了飛利浦公司RespirTech收集的成年支氣管擴張患者自我報告結果的登記數據。這個數據庫現在是世界上最大的支氣管擴張症研究登記。
According to the American Lung Association, nearly 37 million U.S. adults live with a chronic respiratory disease, including cystic fibrosis, chronic obstructive pulmonary disease (COPD), and bronchiectasis [1]. Exacerbations of these chronic respiratory diseases can be a major source of costs for healthcare systems and insurers, as hospitalizations and readmissions result in billions of dollars of additional healthcare costs each year. Such exacerbations have a negative impact on quality of life, as patients experiencing numerous episodes report symptoms such as low energy, shortness of breath, and excess mucus production. This study observed chronic respiratory patients receiving HFCWO therapy, an airway clearance technique that uses a fitted vest to apply external chest wall oscillations in an attempt to combat these issues.
根據美國肺臟協會的數據，近3700萬美國成年人患有慢性呼吸系統疾病，包括囊性纖維化、慢性阻塞性肺疾病(COPD)和支氣管擴張[1]。這些慢性呼吸道疾病的惡化可能是醫療保健系統和保險公司成本的主要來源，因為住院和重新住院每年導致數十億美元的額外醫療費用。這種惡化對生活質量有負面影響，因為經歷多次發作的患者報告了諸如能量低下、呼吸急促和粘液產生過多等症狀。這項研究觀察了接受HFCWO治療的慢性呼吸系統患者，這是一種呼吸道清除技術，使用合身的背心來應用外部胸壁振盪，試圖對抗這些問題。
The study, “Real-life experience with high-frequency chest wall oscillation vest therapy in adults with non-cystic fibrosis bronchiectasis” [2], found that initiating airway clearance with non-invasive HFCWO therapy is associated with keeping patients out of the hospital, reducing their need for medications, and improving quality of life. It is the largest study of airway clearance use for bronchiectasis to date. After monitoring 2,596 patients using Philips InCourage System, the study concluded that in the first year of vest use, the rate of hospitalization dropped 54.5%, self-reported ability to clear lungs improved from 13.9% to 76.6%, and antibiotic use dropped from 57.7% to 29.9%. As an added benefit beyond the results of the study, thePhilips InCourage Systemis uniquely supported by patient-centric services designed to optimize product use, improve patient-provider communication, and encourage therapy adherence.
《成人非囊性纖維支氣管擴張症患者高頻胸壁振動背心治療的真實體驗》研究[2]研究發現，使用非侵入性HFCWO療法開始呼吸道清除與患者遠離醫院、減少他們對藥物的需求以及提高生活質量有關。這是迄今為止最大規模的關於使用呼吸道清除劑治療支氣管擴張的研究。在監測了2596名使用飛利浦Incourage系統的患者後，研究得出結論，在使用背心的第一年，住院率下降了54.5%能力肺部清潔由13.9%提高到76.6%，抗生素使用率從57.7%下降到29.9%。除了研究結果之外，飛利浦Incourage系統還獲得了以患者為中心的服務的獨特支持，這些服務旨在優化產品使用，改善患者與提供者的溝通，並鼓勵堅持治療。
“Chronic respiratory conditions, like bronchiectasis and COPD, contribute to significant healthcare costs each year between hospitalizations and readmissions. Now, more than ever, health systems and insurers are looking for ways to mitigate these costs, while also balancing quality care,” said Gary Hansen, Director of Scientific Affairs with RespirTech, a Philips Company. “This study shows positive results that HFCWO therapy delivered by the InCourage system, coupled with RespirTech’s patient-centered service model, can help to reduce hospitalizations and antibiotic use for chronic respiratory patients, while also improving their overall quality of life.”
慢性呼吸系統疾病，如支氣管擴張症和慢性阻塞性肺病，每年在住院和再住院之間造成巨大的醫療費用。現在，健康系統和保險公司比以往任何時候都更在尋找方法來降低這些成本，同時也在平衡高質量的醫療保健，“飛利浦公司旗下呼吸技術公司科學事務董事的加里·漢森説。這項研究表明，鼓勵系統提供的HFCWO療法，加上呼吸科技公司以患者為中心的服務模式，可以幫助減少慢性呼吸道患者的住院和抗生素使用，同時還可以提高他們的整體生活質量。
According to William S., a participant in the study, “I couldn’t walk across the room, take a shower or get dressed without losing my breath before I used this system. I [now] use the system three times a day for 30 minutes. [It has] eliminated the need for antibiotics for constant lung infections. It has been 1.5 years since my last lung infection. It used to be every two months.” [3]
威廉·S是這項研究的參與者之一，他説：“在我使用這個系統之前，我無法在穿過房間、洗澡或穿衣服時不喘不過氣來。我[現在]每天使用該系統三次，每次30分鐘。[它有]消除了對持續肺部感染的抗生素的需求。我上次肺部感染已經有一年半了。以前是每兩個月一次。[3]
In 2017, Philips acquired Minnesota-based RespirTech to complement and expand Philips Respiratory Care solution portfolio. To learn more about Philips InCourage system and airway clearance solutions including RespirTech patient services, please visitwww.RespirTech.com.
2017年，飛利浦收購了總部位於明尼蘇達州的RespirTech，以補充和擴大飛利浦呼吸護理解決方案產品組合。欲瞭解更多有關飛利浦Incourage系統和呼吸道清理解決方案(包括RespirTech患者服務)的信息，請訪問www.RespirTech.com。
[1] American Lung Association,https://www.lung.org/about-us/mission-impact-and-history/our-impact#:~:text=Improving%20Quality%20of%20Life%20for,includes%20emphysema%20and%20chronic%20bronchitis.[2] Barto, et. al, “Real-life experience with high-frequency chest wall oscillation vest therapy in adults with non-cystic fibrosis bronchiectasis.”Therapeutic Advances in Respiratory Disease,vol 14, June 15, 2020,https://journals.sagepub.com/doi/full/10.1177/1753466620932508. Barto is a consultant for RespirTech. Daignault and Hansen are employees of RespirTech.[3] Individual results may vary
[1]美國肺臟協會，https://www.lung.org/about-us/mission-impact-and-history/our-impact#：~：text=Improving%20Quality%20of%20Life%20for，includes%20emphysema%20and%20chronic%20bronchitis.[2]巴託等人。成人非囊性纖維支氣管擴張症患者使用高頻胸壁振盪背心治療的真實體驗>，《呼吸系統疾病治療進展》，第14卷，2020年6月15日，https://journals.sagepub.com/doi/full/10.1177/1753466620932508.。巴託是RespirTech的顧問。Daignault和Hansen是RespirTech的員工。[3]個別結果可能會有所不同
For further information, please contact:
如需更多信息，請聯繫：
Meredith AmorosoPhilips Global Press OfficeTel: +1-724-584-8991E-mail:meredith.amoroso@philips.com
梅雷迪斯·阿莫羅索飛利浦全球新聞處電話：+1-724-584-8991E-mail:meredith.amoroso@philips.com
About Royal Philips
關於皇家飛利浦
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found atwww.philips.com/newscenter.
皇家飛利浦(NYSE：PHG，AEX：PHIA)是一家領先的健康技術公司，專注於改善人們的健康，並使從健康生活和預防到診斷、治療和家庭護理的健康連續體系取得更好的結果。飛利浦利用先進的技術和深入的臨牀和消費者洞察力提供集成的解決方案。該公司總部設在荷蘭，是診斷成像、圖像引導治療、患者監測和健康信息學以及消費者健康和家庭護理領域的領先者。飛利浦2019年的銷售額為195億歐元，員工約81,000人，銷售和服務遍及100多個國家。有關飛利浦的新聞可以在www.Philips.com/newscenter上找到。
Attachments
附件
InCourage Patient Playing Games
鼓勵耐心玩遊戲
Philips InCourage vest
飛利浦鼓勵背心
譯文內容由第三人軟體翻譯。